Logo image of EXPR

EXPRESS INC (EXPR) Stock Fundamental Analysis

NYSE:EXPR - New York Stock Exchange, Inc. - US30219E2028 - Common Stock - Currency: USD

2.29  +0.06 (+2.69%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to EXPR. EXPR was compared to 120 industry peers in the Specialty Retail industry. While EXPR is still in line with the averages on profitability rating, there are concerns on its financial health. EXPR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

In the past year EXPR has reported negative net income.
EXPR had a negative operating cash flow in the past year.
In multiple years EXPR reported negative net income over the last 5 years.
In multiple years EXPR reported negative operating cash flow during the last 5 years.
EXPR Yearly Net Income VS EBIT VS OCF VS FCFEXPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M -400M

1.2 Ratios

EXPR has a Return On Assets of 12.19%. This is amongst the best in the industry. EXPR outperforms 88.28% of its industry peers.
EXPR's Return On Equity of 120.91% is amongst the best of the industry. EXPR outperforms 97.66% of its industry peers.
Industry RankSector Rank
ROA 12.19%
ROE 120.91%
ROIC N/A
ROA(3y)-2.64%
ROA(5y)-3.25%
ROE(3y)-1730.52%
ROE(5y)-1046.08%
ROIC(3y)N/A
ROIC(5y)N/A
EXPR Yearly ROA, ROE, ROICEXPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

1.3 Margins

With an excellent Profit Margin value of 10.01%, EXPR belongs to the best of the industry, outperforming 92.97% of the companies in the same industry.
EXPR's Profit Margin has improved in the last couple of years.
EXPR's Gross Margin of 22.40% is on the low side compared to the rest of the industry. EXPR is outperformed by 76.56% of its industry peers.
EXPR's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 10.01%
GM 22.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y78.26%
GM growth 3Y1.31%
GM growth 5Y-0.5%
EXPR Yearly Profit, Operating, Gross MarginsEXPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20

1

2. Health

2.1 Basic Checks

EXPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
EXPR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, EXPR has less shares outstanding
Compared to 1 year ago, EXPR has an improved debt to assets ratio.
EXPR Yearly Shares OutstandingEXPR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
EXPR Yearly Total Debt VS Total AssetsEXPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of 0.97, we must say that EXPR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of EXPR (0.97) is worse than 69.53% of its industry peers.
A Debt/Equity ratio of 1.83 is on the high side and indicates that EXPR has dependencies on debt financing.
EXPR has a Debt to Equity ratio of 1.83. This is in the lower half of the industry: EXPR underperforms 67.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.83
Debt/FCF N/A
Altman-Z 0.97
ROIC/WACCN/A
WACC15.82%
EXPR Yearly LT Debt VS Equity VS FCFEXPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 0.98 indicates that EXPR may have some problems paying its short term obligations.
With a Current ratio value of 0.98, EXPR is not doing good in the industry: 86.72% of the companies in the same industry are doing better.
EXPR has a Quick Ratio of 0.98. This is a bad value and indicates that EXPR is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.19, EXPR is doing worse than 85.94% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.19
EXPR Yearly Current Assets VS Current LiabilitesEXPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

3

3. Growth

3.1 Past

The earnings per share for EXPR have decreased strongly by -521.75% in the last year.
The Earnings Per Share has been growing by 76.94% on average over the past years. This is a very strong growth
Looking at the last year, EXPR shows a decrease in Revenue. The Revenue has decreased by -8.11% in the last year.
Measured over the past years, EXPR shows a decrease in Revenue. The Revenue has been decreasing by -2.89% on average per year.
EPS 1Y (TTM)-521.75%
EPS 3YN/A
EPS 5Y76.94%
EPS Q2Q%29.1%
Revenue 1Y (TTM)-8.11%
Revenue growth 3Y-2.63%
Revenue growth 5Y-2.89%
Sales Q2Q%4.6%

3.2 Future

Based on estimates for the next years, EXPR will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.01% on average per year.
The Revenue is expected to grow by 2.32% on average over the next years.
EPS Next Y-135.77%
EPS Next 2Y14.55%
EPS Next 3Y16.01%
EPS Next 5YN/A
Revenue Next Year-1.98%
Revenue Next 2Y2.16%
Revenue Next 3Y2.32%
Revenue Next 5YN/A

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EXPR Yearly Revenue VS EstimatesEXPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B 2B
EXPR Yearly EPS VS EstimatesEXPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -20 -40 -60 -80 -100

0

4. Valuation

4.1 Price/Earnings Ratio

EXPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EXPR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EXPR Price Earnings VS Forward Price EarningsEXPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EXPR Per share dataEXPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 200 300 400

4.3 Compensation for Growth

EXPR's earnings are expected to grow with 16.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.55%
EPS Next 3Y16.01%

0

5. Dividend

5.1 Amount

No dividends for EXPR!.
Industry RankSector Rank
Dividend Yield N/A

EXPRESS INC

NYSE:EXPR (3/6/2024, 8:04:00 PM)

2.29

+0.06 (+2.69%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)11-30 2023-11-30/bmo
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners197.99%
Ins Owner Change0%
Market Cap8.59M
Analysts82.86
Price Target20.4 (790.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.5%
Min EPS beat(2)3.19%
Max EPS beat(2)19.81%
EPS beat(4)3
Avg EPS beat(4)1.52%
Min EPS beat(4)-31.14%
Max EPS beat(4)19.81%
EPS beat(8)6
Avg EPS beat(8)57.46%
EPS beat(12)10
Avg EPS beat(12)110.69%
EPS beat(16)11
Avg EPS beat(16)59.58%
Revenue beat(2)0
Avg Revenue beat(2)-4.35%
Min Revenue beat(2)-5.54%
Max Revenue beat(2)-3.17%
Revenue beat(4)0
Avg Revenue beat(4)-4.56%
Min Revenue beat(4)-6.05%
Max Revenue beat(4)-3.17%
Revenue beat(8)1
Avg Revenue beat(8)-3.63%
Revenue beat(12)3
Avg Revenue beat(12)-2.74%
Revenue beat(16)3
Avg Revenue beat(16)-5.37%
PT rev (1m)21.21%
PT rev (3m)21.21%
EPS NQ rev (1m)-34.22%
EPS NQ rev (3m)-703.11%
EPS NY rev (1m)-7.14%
EPS NY rev (3m)-55.01%
Revenue NQ rev (1m)0.24%
Revenue NQ rev (3m)-4.96%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)-3.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0
P/FCF N/A
P/OCF N/A
P/B 0.06
P/tB 0.06
EV/EBITDA N/A
EPS(TTM)-49.74
EYN/A
EPS(NY)-15.54
Fwd EYN/A
FCF(TTM)-63.72
FCFYN/A
OCF(TTM)-51.35
OCFYN/A
SpS476.52
BVpS39.45
TBVpS39.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 12.19%
ROE 120.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 10.01%
GM 22.4%
FCFM N/A
ROA(3y)-2.64%
ROA(5y)-3.25%
ROE(3y)-1730.52%
ROE(5y)-1046.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y78.26%
GM growth 3Y1.31%
GM growth 5Y-0.5%
F-Score4
Asset Turnover1.22
Health
Industry RankSector Rank
Debt/Equity 1.83
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 80.49%
Cap/Sales 2.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.98
Quick Ratio 0.19
Altman-Z 0.97
F-Score4
WACC15.82%
ROIC/WACCN/A
Cap/Depr(3y)50.21%
Cap/Depr(5y)50.38%
Cap/Sales(3y)1.93%
Cap/Sales(5y)2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-521.75%
EPS 3YN/A
EPS 5Y76.94%
EPS Q2Q%29.1%
EPS Next Y-135.77%
EPS Next 2Y14.55%
EPS Next 3Y16.01%
EPS Next 5YN/A
Revenue 1Y (TTM)-8.11%
Revenue growth 3Y-2.63%
Revenue growth 5Y-2.89%
Sales Q2Q%4.6%
Revenue Next Year-1.98%
Revenue Next 2Y2.16%
Revenue Next 3Y2.32%
Revenue Next 5YN/A
EBIT growth 1Y-924.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-76.87%
EBIT Next 3Y36.9%
EBIT Next 5YN/A
FCF growth 1Y-1482.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3156.62%
OCF growth 3YN/A
OCF growth 5YN/A